MYO9B

Across TCGA pan-cancer cohorts, MYO9B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYO9B data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MYO9B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MYO9B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, ACC, and HNSC are the cancer types where MYO9B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	0.933	0.525	.015	26	view →
ACC	DFS	Median	All	0.120	0.772	<.001	21	view →
HNSC	OS	Median	All	0.120	0.397	.023	10	view →
GBM	OS	Median	All	0.117	0.418	.003	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYO9B–UCEC (DFS)

Open the UCEC breakdown →